This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: C74 | Special Copayment Reduction: V193 | 5% copayment (for 5 years from the cancer patient registration date) C74.0 adrenal cortex, C74.1 adrenal medulla, C74.9 unspecified |
| B. Synonyms | Adrenocortical carcinoma, adrenocortical malignant tumor, malignant pheochromocytoma, Adrenocortical carcinoma (ACC), Adrenal cortical carcinoma, Malignant pheochromocytoma, Adrenal medullary carcinoma, Neuroblastoma (pediatric adrenal medulla) |
| C. Adult onset | Adrenocortical carcinoma: high (mainly in people in their 30s–50s, rarely pediatric type); malignant pheochromocytoma: adult onset; pediatric adrenocortical carcinoma: children (especially age 5 or younger) |
Anatomical description of the adrenal glands began in the 16th century, when Bartolomeo Eustachi (1563) first described them anatomically. However, the endocrine function of the adrenal glands was revealed only from 1855, when the English physician Thomas Addison described adrenal insufficiency (later Addison disease). The steroid hormone synthesis function of the adrenal cortex came to be understood systematically with the discovery of cortisone in the early 20th century (Kendall, Reichstein, Hench — Nobel Prize 1950). Adrenocortical carcinoma (ACC) began to be reported as individual cases from the late 19th century, but its extreme rarity made systematic research difficult until the mid-20th century.
The pathological diagnostic system for ACC was standardized with the publication of the Weiss score in 1984. Weiss assigned points based on nine histological criteria (nuclear grade, mitotic count, atypical mitoses, cytoplasmic clearness, diffuse growth, necrosis, venous invasion, sinusoidal invasion, capsular invasion), and a score of 3 or more suggests malignancy. ENSAT (European Network for the Study of Adrenal Tumors) has systematized the staging system, treatment algorithms, and prognostic factors of ACC through multicenter studies since the 2000s. Mitotane has become the key therapeutic agent for ACC since it was first used in the 1960s.
Most adrenocortical carcinomas are sporadic, and no clear environmental risk factors have been identified. However, several hereditary syndromes markedly increase the risk of ACC. Li-Fraumeni syndrome: ACC is markedly increased in patients with germline TP53 mutations; in southern Brazil in particular, the TP53 p.R337H variant is found at high frequency, and the incidence of pediatric ACC reaches 10–15 times the global average. Beckwith-Wiedemann syndrome: Dysregulation of the IGF2 gene in the 11p15.5 region increases the risk of embryonal malignancies (Wilms tumor, hepatoblastoma, ACC).
Familial adenomatous polyposis (FAP): In carriers of APC gene mutations, the risk of ACC increases through activation of the Wnt/β-catenin signaling pathway. MEN1 gene variants may be associated with adrenocortical nodules and, rarely, ACC. SDH (succinate dehydrogenase) gene (SDHB, SDHC, SDHD) variants are particularly associated with the development of malignant pheochromocytoma/paraganglioma of the adrenal medulla. VHL gene variants are associated with the development of pheochromocytoma. The larger an adrenal incidentaloma (5cm or more), the higher the likelihood of ACC.
The somatic molecular genetics of adrenocortical carcinoma has recently been elucidated systematically through whole-genome analysis. TP53 mutations are found in about 25–30% of sporadic ACC and are strongly associated with prognosis. IGF2 overexpression: IGF2 overexpression due to somatic loss of imprinting of the IGF2 gene (11p15.5) is the most common molecular abnormality, occurring in about 80–90% of all ACC. Activation of IGF2→IGF1R→PI3K-Akt-mTOR signaling promotes adrenocortical cell proliferation. Wnt/β-catenin pathway: Hyperactivation of the Wnt pathway due to activating CTNNB1 (β-catenin) mutations or APC variants occurs in about 30–40% of ACC.
CDKN2A/CDKN2B deletion: Unlimited proliferation due to loss of cell cycle inhibitors. RB1 loss is also frequently present. Increased TERT expression is associated with high-grade ACC. In whole-genome analysis, ACC divides into two representative clusters—a Wnt/β-catenin-active group with a relatively good prognosis and a TP53-mutant/cell cycle-abnormal group with a poor prognosis. In malignant pheochromocytoma/paraganglioma, germline variants in SDHB/C/D, VHL, RET, MAX, TMEM127 are the key genetic factors. SDH-related malignant pheochromocytoma has the highest risk of distant metastasis.
Adrenocortical carcinoma (ACC) is an extremely rare malignancy with a worldwide incidence of only 0.7–2.0 per million population. There are two peaks in the age distribution: a pediatric peak at age 5 or younger (especially related to hereditary Li-Fraumeni syndrome) and an adult peak in the 30s–50s. By sex, it is about 1.5–2 times more common in women than in men. Stage at diagnosis is important; more than 50% are diagnosed already at a locally advanced or distant metastatic stage (ENSAT stage 3–4). In Korea, ACC is very rare at a few dozen cases per year, and there are no separate statistics.
The prevalence of adrenal incidentaloma is known to be about 1–5% with the widespread use of imaging (CT/MRI), and the proportion of ACC among them is about 1–5%. Among incidentalomas, the larger the size (>4cm) and the more heterogeneous or irregular the border on imaging, the higher the likelihood of ACC. Of malignant pheochromocytomas/paragangliomas, about 10% of all pheochromocytomas and about 15–35% of paragangliomas are classified as malignant. Southern Brazil has the world's highest incidence of pediatric ACC owing to the founder effect of the TP53 p.R337H variant.
The pathogenesis of adrenocortical carcinoma is a multistep process beginning in normal adrenocortical cells. IGF2 overexpression is the earliest key molecular event, forming an IGF2→IGF1R autocrine loop that persistently activates the PI3K-Akt-mTOR pathway. This promotes cell growth and survival and inhibits apoptosis. Activation of the Wnt/β-catenin pathway promotes self-renewal and proliferation of adrenocortical progenitor cells; CTNNB1 mutations prevent β-catenin from being degraded, so it accumulates in the nucleus and activates target genes such as c-Myc and cyclin D1.
TP53 loss disables cell cycle arrest (G1/S checkpoint) and the DNA damage response, amplifying genomic instability, which promotes the accumulation of additional abnormalities such as CDKN2A/B deletion and RB1 loss. In pediatric ACC, the TP53 (R337H) variant is a unique mechanism that weakens the pH-sensitive structure of the TP53 protein, inducing loss of function under specific conditions. In malignant pheochromocytoma, loss of SDH complex function → succinate accumulation → HIF-1α activation (pseudohypoxic signaling) → overexpression of angiogenic factors such as VEGF → aggressive tumor progression is the key mechanism.
About 60% of adrenocortical carcinomas are functional tumors that produce endocrine symptoms from excess steroid hormone secretion. Cushing syndrome—cortisol excess: central obesity (buffalo hump, moon face), red cutaneous striae, muscle weakness, osteoporosis, diabetes, hypertension, immunosuppression—is the most common (about 40%). Virilization—androgen excess: in women, hirsutism, amenorrhea, clitoromegaly, deepening of the voice; not prominent in men—is the second most common. In pediatric ACC, virilizing findings (early pubic hair, penile/clitoral enlargement, accelerated growth) are the most common symptoms (about 72%).
In adult ACC, mixed Cushing and virilization symptoms are common. Feminization—estrogen excess: gynecomastia, decreased libido, and erectile dysfunction in men—is rare. Aldosteronism—hypertension, hypokalemia—also occurs rarely. About 40% are nonfunctional tumors that present without endocrine symptoms, with nonspecific symptoms such as abdominal pain, an incidentally discovered abdominal mass, and weight loss. Malignant pheochromocytoma is characterized by the triad of episodic hypertension, headache, palpitations, and sweating.
Signs of Cushing syndrome: central obesity (abdomen, face, neck), moon face, buffalo hump (fat accumulation at the back of the neck), red cutaneous striae (striae rubrae) — especially on the abdomen, thighs, and axillae, proximal muscle weakness (difficulty rising from a seated position), thinning of the skin and easy bruising (bruisability), hypertension, and glucose abnormalities. Biochemical tests for Cushing syndrome: increased 24-hour urinary free cortisol, increased late-evening salivary cortisol, failure to suppress on the 1mg dexamethasone suppression test (cortisol > 1.8 μg/dL).
Signs of virilization: clitoromegaly, deepening of the voice, muscle development, androgenic alopecia, and acne in women. On abdominal palpation, a large tumor may be felt as an abdominal mass. Elevated serum DHEA-S, androstenedione, and testosterone are the biochemical findings of androgen-secreting ACC. On measurement of serum cortisol and ACTH, ACC is characterized by elevated cortisol with suppressed ACTH (ACTH-independent Cushing). On CT, a large adrenal mass (usually >6cm), heterogeneous density, necrosis, and irregular borders suggest ACC.
There is no general population screening program for ACC. However, regular testing is recommended in high-risk hereditary syndromes. In Li-Fraumeni syndrome families (carriers of germline TP53 variants), surveillance for early detection of ACC is performed with annual abdominal ultrasound or MRI. In regions of Brazil with carriers of the TP53 (R337H) variant, regular abdominal ultrasound screening of children is carried out. In children with Beckwith-Wiedemann syndrome, abdominal ultrasound at 4-month intervals is used to monitor for Wilms tumor, hepatoblastoma, and ACC.
When an adrenal incidentaloma is found, structural and functional evaluation is needed. If imaging shows findings suggestive of malignancy, such as size (>4cm), density (>10 HU in non-contrast CT), heterogeneity, irregular borders, or delayed washout, surgical resection is considered. Hormonal function evaluation (24-hour urinary cortisol, dexamethasone suppression test, plasma metanephrines, aldosterone/renin ratio) is also performed for all adrenal incidentalomas. In families with SDH/VHL variants, surveillance for pheochromocytoma is performed with annual MRI and urinary metanephrine measurement.
The diagnosis of adrenocortical carcinoma is made by integrating clinical, biochemical, imaging, histological, and molecular tests. Abdominal CT (triphasic: non-contrast + arterial phase + delayed phase) is the standard for imaging evaluation of adrenal tumors. A value of 10 HU or less on non-contrast CT indicates a high likelihood of benign adenoma, while a value above 10 HU with slow contrast washout (less than 60%) raises suspicion of malignancy or pheochromocytoma. MRI is used to complement CT, and chemical shift imaging distinguishes lipid-rich adenomas. FDG-PET is useful for staging local progression and distant metastasis.
Biochemical tests: cortisol (24-hour urinary free cortisol, late-evening salivary cortisol, 1mg DST), DHEA-S, androstenedione, 17-OH progesterone, estradiol, aldosterone/renin ratio, urinary/plasma metanephrines (to rule out pheochromocytoma). Tissue diagnosis is made after surgical resection by applying the Weiss score, the Ki-67 proliferation index, and immunohistochemistry (SF-1, synaptophysin, inhibin). Adrenal biopsy is considered only when planning nonsurgical treatment after pheochromocytoma has been excluded and is generally avoided. Molecular genetic testing (TP53, CTNNB1, CDKN2A, germline testing) is used for treatment planning and genetic counseling.
The only curative treatment for adrenocortical carcinoma is complete surgical resection (R0 resection). Open or laparoscopic adrenalectomy (early stage, small tumors) is performed, and in advanced stages en bloc resection of adjacent organs may be required. Achieving complete resection (R0) is the most important prognostic factor for survival. Mitotane is the key agent in ACC treatment, directly destroying adrenocortical cells through toxicity and inhibiting steroid synthesis. Adjuvant mitotane after surgery (target blood level 14–20 mg/L) is used to prevent recurrence in high-risk ACC.
In advanced/metastatic ACC, the first-line standard chemotherapy is the EDP-M regimen: etoposide + doxorubicin + cisplatin + mitotane. In the FIRM-ACT trial (NEJM 2012), EDP-M improved progression-free survival compared with mitotane plus streptozotocin and was established as the standard regimen. For second-line treatment of recurrence, gemcitabine + capecitabine + mitotane is used. Immune checkpoint inhibitors (pembrolizumab, avelumab) and targeted agents (lenalidomide, IGF1R inhibitors) are under clinical investigation. In malignant pheochromocytoma, radiolabeled MIBG (I-131) therapy or PRRT (Lu-177 DOTATATE) is used.
The prognosis of adrenocortical carcinoma varies greatly by stage and is generally poor. ENSAT stage 1 (localized, ≤5cm): 5-year survival rate about 66–82%. ENSAT stage 2 (localized, >5cm): 5-year survival rate about 58–64%. ENSAT stage 3 (lymph node metastasis or invasion of adjacent organs): 5-year survival rate about 24–50%. ENSAT stage 4 (distant metastasis): 5-year survival rate about 0–15%. Even after complete resection (R0), recurrence occurs in more than 50%, and the prognosis after recurrence is very poor. The overall 5-year survival rate is about 20–35%, and early detection and complete resection are decisive.
Poor prognostic factors: high stage (ENSAT 3–4), R1/R2 resection (incomplete resection), high Ki-67 (>20%), nonfunctional tumor, TP53 mutation, absence of CTNNB1 mutation, and subtherapeutic mitotane blood levels. The 5-year survival rate of malignant pheochromocytoma varies greatly with the presence of metastasis, and malignant tumors related to SDH variants (especially SDHB) have the highest risk of distant metastasis (5-year survival rate about 36%). Pediatric ACC is more often detected at an early stage than adult ACC and is related to TP53 mutations, but the prognosis after complete resection tends to be somewhat better than in adults.
There is as yet no definite method of preventing adrenocortical carcinoma. Genetic counseling and genetic testing for hereditary ACC syndromes are the most effective preventive strategy. In families with Li-Fraumeni syndrome (germline TP53 variants) and patients with Beckwith-Wiedemann syndrome, early detection and treatment are carried out through regular imaging surveillance (abdominal ultrasound/MRI). In regions with a high frequency of a specific TP53 founder mutation, such as southern Brazil, population genetic screening may be considered. In carriers of SDH gene variants, regular imaging and biochemical testing for early detection of malignant pheochromocytoma/paraganglioma are important.
When an adrenal incidentaloma is found, deciding on active follow-up or early surgery according to size, imaging characteristics, and hormonal function tests can increase the opportunity to resect ACC before it progresses. No specific lifestyle changes for preventing ACC in the general population are known, and no clear environmental carcinogens affecting the adrenal cortex have been identified. Reducing postoperative recurrence with adjuvant drug therapy including mitotane is the best secondary prevention (recurrence prevention) strategy.